Comparison of serum sensitivities of pseudotype retroviruses produced from newly established packaging cell lines of human and feline origins.
To apply retrovirus vectors for in vivo gene therapy in cats, it is necessary to develop vector systems that are not inactivated by cat serum. In this study, the retrovirus packaging cell lines 2SC-1 and AHCeB7 were newly established from human embryonic kidney (HEK) 293 and feline fibroblastic AH927 cells, respectively. Then the sensitivities of pseudotype viruses released from these cell lines to fresh sera from humans and cats were compared. Pseudotype viruses from the 2SC-1 cells were inactivated efficiently by cat serum but not by human serum. Pseudotype viruses from the AHCeB7 cells were also inactivated efficiently by human serum, however they were rather resistant to cat serum. When the xenoantigenicity of the cell lines was examined by flow cytometry, AH927 cells reacted with human serum, however, HEK293 cells did not react with cat serum. These results suggested that pseudotype viruses from 2SC-1 cells were inactivated by the fresh cat serum in an antibody-independent manner. Chelating experiments revealed that certain temperature-sensitive factor(s) other than complements might be involved in the inactivation. The usage of feline cells as packaging cells is suitable for in vivo gene therapy in cats.
Watanabe
Rie
R
Research Center for Emerging Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita, Osaka 565-0872, Japan.
Miyazawa
Takayuki
T
Matsuura
Yoshiharu
Y
D000818:Animals; D000906:Antibodies / Q000276:immunology; D000998:Antiviral Agents / Q000097:blood*; D002415:Cats; D002460:Cell Line; D003165:Complement System Proteins / Q000276:immunology; D004274:DNA, Recombinant; D005822:Genetic Vectors; D006801:Humans; D012194:RNA-Directed DNA Polymerase / Q000378:metabolism; D012190:Retroviridae / Q000235:genetics / Q000254:growth & development*; D014161:Transduction, Genetic; D014162:Transfection; D019065:Virus Assembly; D038301:Virus Inactivation
D000906:Antibodies; D000998:Antiviral Agents; D004274:DNA, Recombinant; D003165:Complement System Proteins; D012194:RNA-Directed DNA Polymerase